Peramivir: Evidence to support the use of the first approved intravenous therapy for influenza

Jeremy Katzen, Michael G. Ison*

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Peramivir, an intravenous neuraminidase inhibitor, was first available in clinical practice during the 2009 A/H1N1 pandemic under an Emergency Use Authorization by the US FDA. As the lone intravenous neuraminidase inhibitor available and with a novel structure compared with the available neuraminidase inhibitors, it was offered as an alternative to patients not responding to existing therapy or without enteric access. Since the expiration of the Emergency Use Authorization, peramivir has undergone multiple clinical trials for the treatment of both uncomplicated influenza infection in the ambulatory setting and complicated influenza infection in the hospitalized setting. With the recent FDA approval of single-dose therapy for uncomplicated influenza infection, we will review the preclinical and clinical data, to date, on peramivir.

Original languageEnglish (US)
Pages (from-to)937-948
Number of pages12
JournalFuture Virology
Volume10
Issue number8
DOIs
StatePublished - Jan 1 2015

Fingerprint

Neuraminidase
Human Influenza
Emergencies
Infection
Pandemics
Therapeutics
Clinical Trials
peramivir

Keywords

  • BCX-1812
  • RWJ-270201
  • antiviral therapy
  • influenza
  • neuraminidase inhibitors
  • peramivir

ASJC Scopus subject areas

  • Virology

Cite this

@article{7156d9f2cce648929c9f3a6daf910b52,
title = "Peramivir: Evidence to support the use of the first approved intravenous therapy for influenza",
abstract = "Peramivir, an intravenous neuraminidase inhibitor, was first available in clinical practice during the 2009 A/H1N1 pandemic under an Emergency Use Authorization by the US FDA. As the lone intravenous neuraminidase inhibitor available and with a novel structure compared with the available neuraminidase inhibitors, it was offered as an alternative to patients not responding to existing therapy or without enteric access. Since the expiration of the Emergency Use Authorization, peramivir has undergone multiple clinical trials for the treatment of both uncomplicated influenza infection in the ambulatory setting and complicated influenza infection in the hospitalized setting. With the recent FDA approval of single-dose therapy for uncomplicated influenza infection, we will review the preclinical and clinical data, to date, on peramivir.",
keywords = "BCX-1812, RWJ-270201, antiviral therapy, influenza, neuraminidase inhibitors, peramivir",
author = "Jeremy Katzen and Ison, {Michael G.}",
year = "2015",
month = "1",
day = "1",
doi = "10.2217/fvl.15.61",
language = "English (US)",
volume = "10",
pages = "937--948",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "8",

}

Peramivir : Evidence to support the use of the first approved intravenous therapy for influenza. / Katzen, Jeremy; Ison, Michael G.

In: Future Virology, Vol. 10, No. 8, 01.01.2015, p. 937-948.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peramivir

T2 - Evidence to support the use of the first approved intravenous therapy for influenza

AU - Katzen, Jeremy

AU - Ison, Michael G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Peramivir, an intravenous neuraminidase inhibitor, was first available in clinical practice during the 2009 A/H1N1 pandemic under an Emergency Use Authorization by the US FDA. As the lone intravenous neuraminidase inhibitor available and with a novel structure compared with the available neuraminidase inhibitors, it was offered as an alternative to patients not responding to existing therapy or without enteric access. Since the expiration of the Emergency Use Authorization, peramivir has undergone multiple clinical trials for the treatment of both uncomplicated influenza infection in the ambulatory setting and complicated influenza infection in the hospitalized setting. With the recent FDA approval of single-dose therapy for uncomplicated influenza infection, we will review the preclinical and clinical data, to date, on peramivir.

AB - Peramivir, an intravenous neuraminidase inhibitor, was first available in clinical practice during the 2009 A/H1N1 pandemic under an Emergency Use Authorization by the US FDA. As the lone intravenous neuraminidase inhibitor available and with a novel structure compared with the available neuraminidase inhibitors, it was offered as an alternative to patients not responding to existing therapy or without enteric access. Since the expiration of the Emergency Use Authorization, peramivir has undergone multiple clinical trials for the treatment of both uncomplicated influenza infection in the ambulatory setting and complicated influenza infection in the hospitalized setting. With the recent FDA approval of single-dose therapy for uncomplicated influenza infection, we will review the preclinical and clinical data, to date, on peramivir.

KW - BCX-1812

KW - RWJ-270201

KW - antiviral therapy

KW - influenza

KW - neuraminidase inhibitors

KW - peramivir

UR - http://www.scopus.com/inward/record.url?scp=84940648519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940648519&partnerID=8YFLogxK

U2 - 10.2217/fvl.15.61

DO - 10.2217/fvl.15.61

M3 - Article

AN - SCOPUS:84940648519

VL - 10

SP - 937

EP - 948

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 8

ER -